Description
- The FDA has fast-tracked Psilocybin and Ketamine as anti-depressant treatments, which cause immediate improvement in depressive symptoms.
- Low-energy lasers have been developed that can stimulate these areas directly and painlessly to relieve symptoms in treatment-resistant patients suffering from major depression.
- Scientists are developing genetically 'thumbprinted' antidepressants that can be individually tailored to match a person's DNA increasing their effectiveness.
- Inflammation in the body and the brain is a prominent component of depressive illness, to the point that anti-inflammatory agents are useful in the treatment of depression.
- Incredible progress with gene therapy including a treatment overcoming the BDNF gene mutation that interferes with resiliency, promotes vulnerability to depression, and inhibits the capacity of antidepressants to work effectively.
Author: Philip William Gold
Publisher: Twelve
Published: 08/15/2023
Pages: 272
Binding Type: Hardcover
Weight: 1.00lbs
Size: 9.27h x 6.34w x 0.96d
ISBN13: 9781538724613
ISBN10: 1538724618
BISAC Categories:
- Medical | Mental Health
- Psychology | Psychopathology | Depression
- Medical | Neuroscience
About the Author
Dr. Philip W. Gold is one of the world's leading researchers of depressive illness. Since 1974, he has worked at the National Institute of Health where he has served as Chief of Neuroendocrine Research and Senior Investigator in the National Institute of Mental Health Intramural Research Program, and Chief of the Section on Neuroendocrinology. For over 20 years, he headed one of the country's leading clinical research laboratories consisting of 30 individuals at the National Institutes of Health Clinical Center in the study of the biological basis of depressive illness.